Latest News & Features
Americas
Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis. 6 November 2017
Americas
A US House of Representatives committee has called a hearing on the issue of IP rights being owned by entities that claim sovereign immunity. 6 November 2017
Americas
Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD). 3 November 2017
Americas
Canada-based Valeant has agreed to pay $13 million to biotechnology company PDL BioPharma to settle a dispute over royalties. 2 November 2017
Americas
Watson Laboratories has secured a win at the US Court of Appeals for the Federal Circuit, after the court said Watson did prove that Bayer’s patent claims were obvious. 2 November 2017
Big Pharma
The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan. 1 November 2017
Americas
Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat. 1 November 2017
Asia
Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more. 1 November 2017
Americas
With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out. 1 November 2017
Americas
Following the signing of a historic trade agreement with the EU, Canada now has a system of patent term extension. LSIPR considers the impact for pharmaceutical patentees. 1 November 2017